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Abstract 
Spinal Muscular Atrophy (SMA) is a genetic neurological disease that causes infant mortality; no 
effective therapies are currently available. SMA is due to homozygous mutations and/or deletions 
in the Survival Motor Neuron 1 (SMN1) gene and subsequent reduction of the SMN protein, 
leading to the death of motor neurons. However, there is increasing evidence that in addition to 
motor neurons, other cell types are contributing to SMA pathology. In this review, we will discuss 
the involvement of non-motor neuronal cells, located both inside and outside the central nervous 
system, in disease onset and progression. These contribution of non-motor neuronal cells to 
disease pathogenesis has important therapeutic implications: in fact, even if SMN restoration in 
motor neurons is needed, it has been shown that optimal phenotypic amelioration in animal 
models of SMA requires a more widespread SMN correction. It will be crucial to take this 
evidence into account before clinical translation of the novel therapeutic approaches that are 
currently under development. 
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1. Introduction 
Spinal muscular atrophy (SMA) is the most common genetic neurological disease leading to 
infant mortality. It is characterized predominantly by spinal motor neuron loss, muscle 
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atrophy and motor impairment [1,2]. There is currently no effective treatment for this 
disease, although several promising therapeutic strategies are under development [3,4]. 
SMA is caused by mutations in the Survival Motor Neuron 1 (SMN1) gene, which result in 
functional SMN protein deficiency, leading to motor neuron degeneration. 
 
SMN is ubiquitously expressed and its well-characterized function is linked to a critical 
pathway of RNA metabolism: the small nuclear ribonucleic proteins’ (snRNP) biogenesis 
[5]. Briefly SMN, in collaboration with partner proteins, catalyzes the assembly of snRNPs, 
which are the building blocks for pre-mRNA splicing [5]. Highlighting the importance of 
this function, which is essential for every cell, the complete loss of SMN protein results in 
embryonic lethality in knockout animals [6]. In contrast, SMA is caused by various degrees 
of reduction in SMN levels. In line with this, Cre-Lox transgenic rodent models in which 
full-length SMN is completely ablated in specific tissues, have shown that the absence of 
SMN protein leads to dramatic tissue-specific defects that are more severe than the typical 
SMA phenotype, where residual SMN protein levels are still present [7,8]. 
 
SMA is a neurodegenerative condition and is widely referred to as a motor neuron disease. 
Although some researchers consider that the motor neuron is the primary site of pathology 
in SMA and SMN restoration in these cells is sufficient for therapy [7,9,10]; other work 
suggests that multiple organs contribute to the phenotype, in particular in the most severe 
forms of SMA [11,12]. From a clinical point of view, SMA is classified into three types 
based on age of onset and clinical course. Type I SMA is the most severe infant form, type 
II is an intermediate form affecting toddlers, and type III is a mild juvenile form. Type 1 and 
type 0 SMA patients, can present some systemic signs and symptoms such as autonomic 
dysfunction, cardiac impairment, and, rarely, skin necrosis [13,14]. Indeed, these systemic 
features are even more prominent in the most widely used severe transgenic mouse models 
of SMA [15-17]. When SMN levels are dramatically diminished, this more widespread 
pathology is probably linked to the general RNA metabolism pathways described above 
[17]. On the other hand, in the mildest forms of SMA, in which SMN levels are relatively 
higher, only motor neurons are affected, suggesting that this cell type is more sensitive to 
SMN reduction. Thus, it is legitimate to hypothesize that there is a variable threshold of 
susceptibility to SMN reduction in different cell types. The level of SMN in other tissues 
could be important to better understand the role of SMN protein, and the effects of its 
depletion could be useful to develop new therapeutic strategies against SMA. 
 
Humans and bonobos are the only species in which two copies of paralogous inverted SMN 
genes in chromosome 5 are present [18]. The paralogous gene SMN2 differs from SMN1 by 
a single C-to-T transition in exon 7 that modifies a splicing modulator and causes deletion of 
exon 7 in 90% of SMN2 mRNA transcripts [19]. The SMN protein lacking exon 7 does not 
oligomerize efficiently and is quickly degraded, leading to the reduction of total SMN 
levels. The SMN2 gene produces approximately 10% of full-length SMN2 protein [19], 
which is a major modulator of SMA clinical phenotype 
 
As a result, only a small percentage of full-length, functional and stable SMN protein is 
produced from SMN2. Due to this partial SMN production, the number of SMN2 copies is 
inversely correlated with disease severity in patients [20]. In fact, it is known that there are 
 
 
asymptomatic subjects carrying homozygous SMN1 gene mutations and multiple copies of 
SMN2; while at the other extreme, the total absence of SMN products is invariably fatal [5]. 
 
In this review, we will discuss the involvement of non-motor neuronal cells, located both 
inside and outside the central nervous system (CNS), in SMA pathogenesis. We will discuss 
the different mechanisms that could play a role in disease initiation and progression, as well 
as the important implications for the optimal design of novel effective therapeutic strategies. 
Motor neurons are the predominant target in the majority of therapeutic approaches. 
However, the consideration of other cell types affected by SMN deficiency, at different time 
points of the disease, could be crucial for therapeutic success in SMA patients. Taking into 
consideration all these aspects, it is crucial to focus on targeting both motor neurons and 
other cell types and to define the therapeutic window when interventions can still be 
meaningful, when developing new therapeutic strategies. 
 
2. Therapeutic implications in non-motor neuron cell types 
Rodents, in contrast to humans, carry only the smn gene. For the generation of mouse 
models of SMA, scientists have combined the genetic deletion of endogenous mouse smn 
with the insertion of several copies of human SMN2 [21]. The genetic insertion of two 
copies of SMN2 and of a transgene missing the exon 7 sequence (SMNΔ7) in smn knockout 
murine embryonic cells has led to the generation of a mouse strain known as SMNΔ7 [22]. 
SMNΔ7 mice are widely employed in pre-clinical studies of SMA since they recapitulate 
many key aspects of the disease, including severe progressive muscle weakness and an 
average lifespan of about 2 weeks [22]. Although there is limited muscle denervation and 
overall motor neuron loss, specific muscle groups and motor neuron subsets in these mice 
show greater vulnerability compared to others [23-25]. 
 
Several groups have shown that the restoration of SMN1 in SMA mice, using a motor 
neuron specific promoter (homeobox gene 9 (HB9) or choline acetyltransferase (ChAT)), 
resulted only in a modest extension of survival [9,26,27]. Conversely, SMN1 expression in 
SMA mice using a promoter highly expressed both in neurons and astrocytes (prion 
promoter), significantly extended their survival [7]. These crucial findings, together with 
others, suggest that astrocytes, sensory neurons, Schwann cells and skeletal muscle may all 
contribute to the expression of the disease and its associated motor neuron loss 
[28,29,27,30,25,31,32]. Additional evidence of the potential key role of non–motor neuronal 
cells in SMA pathogenesis was recently provided by an effort to up-regulate SMN protein, 
introducing the wild-type SMN1 gene [33-36], or by modulating SMN2 splicing with 
oligonucleotides or small molecules in mice (for review see [4], [37,38]. Several recent 
studies have demonstrated that these strategies can significantly increase survival of SMA 
mice [39-44,38]. In particular Foust and his group obtained the most profound phenotypic 
correction in terms of rescue of motor function, neuromuscular physiology and life span 
[40]. Here, vascular delivery of scAAV9 encoding SMN at postnatal day 1 in SMA pups 
was employed to increase levels of SMN protein. In contrast, Hua used a different strategy 
based on antisense oligonucleotides that effectively corrected SMN2 splicing and restored 
SMN expression in motor neurons. In agreement with the first study, the systemic 
administration of gene-correcting agents to neonates robustly rescued the severe SMA mice 
 
 
phenotype [16]. Also, in a recent paper Hua and collaborators demonstrated that increasing 
SMN exclusively in peripheral tissues completely rescued necrosis in mild SMA mice, and 
significantly extended survival of severe SMA mice, with noticeable improvements in motor 
neuron survival, neuromuscular junction integrity, and motor function. Accordingly, they 
conclude that the SMA phenotype in murine models is not the result of a cell-autonomous 
defect of motor neurons [45]. 
 
3. Role of non-motor neuronal cells located inside the CNS 
3.1. Interneurons and sensory neurons 
Numerous in vitro and in vivo studies have shed light on discrete alterations in sensory 
neurons and interneurons in SMA. For instance, Jablonka and collaborators (2006) (Table 1) 
have demonstrated that in Smn-deficient sensory neurons isolated from the severely affected 
SMA mouse model (Smn −/−; SMN2), growth cones are smaller, neurites are shorter, and 
levels of both β-actin mRNA and protein are reduced in comparison to neurons from control 
animals; without affecting the survival of these cells in culture [29]. In vivo, the sensory 
neurons of embryos from the same SMA mouse model did not develop normally. In 
particular, they exhibited smaller terminals in the skin and altered neurite growth and growth 
cone morphology compared to controls [29]. In the relatively less severe SMA mouse 
model, SMNΔ7, early alterations of monosynaptic connections between proprioceptive 
(sensory) neurons and motor neurons, such as reduction in the number of VGluT1+ synaptic 
terminals on motor neuron soma were shown to precede motor neuron loss [25]. 
Furthermore, a recent study performed by Zhang and colleagues, has found that motor 
neuron loss is preceded by a dysregulation of mRNAs critical for synaptic formation and 
sensory-motor circuitry in SMA mice spinal cord [46]. Importantly, abnormal conduction 
velocity and axonal degeneration of sensory neurons are also reported in severe SMA type I 
patients [47]. In a Drosophila model of SMA, the groups of McCabe (2012), and Pellizzoni 
(2012), have shown that when SMN is deleted in sensory neurons, their excitability is 
reduced causing secondary motor neuron dysfunction [28,48] (Table 1). In 2012, 
Pellizzoni’s group identified a novel gene called Stasimon, which is involved in U12 related 
splicing defects in the context of reduced SMN levels [48]. They demonstrated that aberrant 
splicing of Stasimon in cholinergic sensory neurons and interneurons causes SMN-related 
phenotypes, while its re-expression leads to the complete restoration of neuromuscular 
junction activity and muscle size. 
 
In light of these studies suggesting that SMN levels and function in sensory neurons and 
interneurons contribute indirectly to motor neuron function, it has been hypothesized that 
some primary defects appearing in afferent sensory neurons may contribute to, or may 
exacerbate a secondary motor neuron dysfunction and loss [9,24,27]. In contrast, other 
studies point to motor neuron dysfunction triggering secondary sensory and interneuron 
deficits in SMA [9,27,49,50]. In a cellular model employing iPSC-derived neurons, Schwab 
and Ebert (2014) (Table 1) have used a direct co-culture approach to assess whether sensory 
neurons established from SMA-derived iPS cell lines can lead to WT motor neuron loss 
[51]. They found that SMA iPSC-derived sensory neurons have a negligible impact on 
motor neuron survival, or expression of glutamate transporters (VGLUT1, VGLUT2) in 
 
 
neurites and cell bodies of motor neuron; concluding that SMN-deficient sensory neurons 
are not the primary trigger of motor neuron loss [51]. As described above, it has been shown 
that motor neuron loss is preceded by a small reduction in VGLUT1+ bouton numbers on 
sensory neurons [24]. From a neuropathological point of view, at the end stage of the 
disease, the number of VGLUT1+ synapses decreases in motor neurons but not in sensory 
neurons, while VGLUT2 excitatory boutons reduce in L3–L5 lateral motor neurons, raising 
the possibility that synaptic defects might appear in interneuronal circuits [24]. This 
evidence lead Thirumalai and collaborators to conclude that the loss of proprioceptive 
synapses on motor neurons may be secondary to motor neuron pathology [50]. Similarly, 
amelioration of electrophysiological deficits and loss of sensory-motor synapses could be 
achieved through increasing SMN levels in motor neurons in SMNΔ7 mice, and even in the 
severe murine model, suggesting that the reduced levels of SMN in motor neurons 
contributes to the motor circuit dysfunction [9,52,27]. 
 
In SMA, the de-afferentation of motor neurons is an early event leading to motor 
impairment [25]. Moreover, Reanult and co-workers (1983) showed reduced H-reflexes in 
type I human SMA patients that is responsible for the muscle weakness caused not only by 
proprioceptive abnormalities but also complicated by neuromuscular denervation and motor 
neuron loss [53]. In addition to abnormal sensory nerve conduction velocity [54,55,47], 
nerve biopsies have revealed sensory axonal degeneration in SMA [47]. Overall, it remains 
unclear whether the loss of sensory-motor synapses is the cause, or the consequence of 
motor neuron loss; further studies are clearly needed to decipher the sequence of events in 
the pathophysiology of SMA. 
 
3.2. Astrocytes 
Astrocytes are the most abundant cell type in the CNS and are present both in white and 
grey matter. These cells are characterized by a star-shaped cytoplasm, comprised of 
intermediate filaments (glial fibers), extending numerous processes that surround adjacent 
blood vessels and neurons. Astrocytes have different roles, such as maintaining neuronal 
functions, supporting synaptic interactions, and serving as neural precursors in adult 
neurogenic regions (Figure 1). Moreover, through the reuptake of neurotransmitters, they 
can contribute to overall synaptic activity; and are a critical component of the blood-brain 
barrier (BBB), regulating the transport of different molecules across this barrier. [56]. 
Multiple cellular studies have demonstrated that astrocytes are able to release proteins 
involved in the control of neuronal maturation and differentiation. Through the release of 
neurotrophic factors, including neurotrophin-3 (NT-3) [57], brain-derived neurotrophic 
factor (BDNF), and nerve growth factor (NGF), astrocytes can enhance neural survival and 
control both neuronal differentiation and growth [58]. Furthermore, other molecules, such as 
S100B which is a glial-specific protein expressed primarily by astrocytes, can be released 
and exert neuroprotective effects against glutamate excitoxicity [59]. 
 
In a neurodegenerative disorder such as SMA, there is growing evidence that astrocytic 
functions are disrupted, giving rise to the hypothesis that astrocytes could contribute to the 
disease process. In fact, during disease progression, astrocytes can become reactive 
exhibiting both morphological and functional changes. McGivern and collaborators recently 
 
 
demonstrated that astrocytes in the SMAΔ7 mouse spinal cord and even astrocytes derived 
from SMA-induced pluripotent stem cells show morphological and cellular alteration 
indicative of activation before the motor neuron loss [30] (Table 1). This indicates that there 
may be a direct consequence of SMN deficiency intrinsic to astrocytes, and that disruption 
of their function may be due to this loss rather than because of altered neuronal-glial 
signaling. No significant differences were reported between wild-type (WT) and SMA 
mouse astrocytes in early post natal days, but at post natal day 9 SMA astrocytes exhibited 
augmented cell bodies, increased expression of GFAP in the cytoplasm, and thin retracted 
processes. Moreover, reactive astrocytes produce pro-inflammatory cytokines, which can 
trigger an apoptotic cascade and motor neuron loss, in particular through ERK1 and ERK2, 
which are members of the MAPK signaling pathway [30]. McGivern and colleagues (2013) 
have hypothesized that increased phosphorylation of ERK1/2 observed in SMA iPSC- 
derived astrocytes, can have a direct role in apoptosis’ induction through an increased 
expression of pro-inflammatory and pro-apoptotic cytokines such as TNFα, IL-1 and IL-6 
[60-62]. In the context of growth factor deprivation, the same group also showed reduced 
secretion of GDNF in SMA iPSC-derived astrocyte cultures, which can be an indirect signal 
for the activation of the apoptotic pathway involving ERK. Astrocyte communication with 
other astrocytes and neurons can also take place through gap junctions, adenosine 
triphosphate (ATP) release, and calcium-dependent glio-transmission [63]. In a cellular 
model, McGivern and colleagues found that there is a dysregulation of basal calcium and 
decreased response to ATP stimulation, confirming abnormal astrocyte function [30] (Figure 
1). Rindt and colleagues examined the involvement of SMN deficiency specifically in 
astrocytes in post-mortem human tissue and in vivo models of SMA. They reported 
prominent astrogliosis in end-stage SMA mice as well as post-mortem patient spinal cords. 
Importantly, restoration of SMN protein levels in astrocytes, using a viral vector-based 
approach, resulted in increased survival in both severe and intermediate models of SMA. In 
addition to an improvement of neuromuscular circuitry, the increased expression of 
proinflammatory cytokines was partially normalized in treated mice, suggesting that 
astrocytes directly contribute to the pathogenesis of SMA [64]. 
 
It is important to note that some groups have demonstrated that motor neuron loss is 
detectable only at the end stage of SMA [23,22]. As is commonly observed in other 
neurodegenerative diseases, the earliest structural defects appear distally, involving the 
neuromuscular synapse in the case of SMA. Prior to death of the motor neuron, there are 
pre-synaptic defects that include loss of terminal arborization as well as intermediate 
filament aggregation, which causes intermittent neurotransmission failures [65]. For this 
reason, it may be inferred that MN death is a late event in SMA pathogenesis, preceded by 
the activation of astrocytes leading to secondary motor neuron degeneration [56]. As 
discussed above, cellular studies have demonstrated that astrocytes participate in the 
regulation of synaptic function by providing an optimal presynaptic environment, triggering 
synaptic maturation, and maintaining synaptic activity and stability [66]. In 
neurodegenerative diseases, their function becomes deregulated, leading to the loss of 
central synapses, as showed by Tarabal and collaborators [67] (Table 1). 
 
 
 
 
Overall, there is growing evidence suggesting that although the expression of SMN in motor 
neurons is essential, its restoration is not sufficient to significantly enhance survival in 
mouse models of SMA. When SMN1 is expressed highly in both astrocytes and MNs, 
survival is maximized [26,30]. These data implicate astrocytes in the pathogenesis of SMA 
and indicate that astrocytes could be an additional target for therapeutic intervention. 
 
3.3. Microglia 
Microglia represent the endogenous immune cells in spinal cord and in brain and mediate 
the innate immune response in the CNS to various types of pathogenic insults. Microglia are 
derived from hematopoietic stem cells, particularly precursors of the monocyte and 
mesodermal lineages. Micro and macroglial cells have an important role in the formation, 
function and elimination of synapses under normal and pathologic conditions (Figure 1) 
[68].. Neuroinflammation plays a key role in the pathology of several neurodegenerative 
diseases, such as Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, and 
amyotrophic lateral sclerosis (ALS) [70-75]. In the case of SMA, microglial activation is 
observed early in the patient’s spinal cord [67]; however the pathological role of microglial 
cells in SMA has not yet been fully characterized. Recently, Tarabal and colleagues [67] 
(Table 1) detected activated microglia in lumbar spinal cord at different stages of a murine 
model of SMA [early post-natal, presymptomatic (P4-5), early symptomatic (P7-8), and end 
stage (P14-15)]. Immunoreactivity for the specific microglial marker, IbaI, was markedly 
increased, surrounding motor neurons in the ventral horn, in a time-dependent fashion in the 
lumbar spinal cord of SMNΔ7 in comparison to WT animals. This increase was significant 
at P7–8, and persisted until the late stages of the disease.. Moreover, in agreement with 
previous studies, they demonstrated an increased loss of glutamatergic terminals in SMNΔ7 
spinal cord during postnatal development [76,24,25,10]. Importantly, in agreement with the 
findings of Mentis [25], but in contrast to Ling and colleagues, the study of Tarabal and co- 
workers showed that the damage of central synapses in SMA precedes MN death [67], as 
discussed above. In contrast, Ling and colleagues (2010) showed that while glutamateric 
terminals on motor neurons are reduced in SMA mice, this occurs in the absence of 
microgliosis in the spinal cord; leading these authors to conclude that neuroinflammation is 
not a major contributing factor to the disease mechanism in models of severe SMA [10]. 
 
The phagocytic function of microglia cells for the clearance of degenerating neurons has not 
been fully considered in the past, but it is an increasingly recognized phenomenon in many 
neurodegenerative diseases [77]. This activity of microglia is also involved in synaptic 
elimination. In a mouse model of SMA, active microglial cells were detected engulfing 
structural complexes including damaged presynaptic terminals and postsynaptic dendrites 
[67]. These findings don’t exclude the relevance of this cell type to the elimination of 
cellular fragments during synapse degeneration [67]. Examination of SMA post mortem 
spinal cord reveals a severe loss of myelinated fibers with numerous glial bundles in the 
anterior horns [78]. These glial bundles are most abundant in the lumbar regions and are 
observed only in the anterior spinal roots and not in the posterior roots. Glial bundles are 
characteristic, but not specific, to SMA and it is hypothesized that they are secondary to 
neuronal degeneration, rather than causing the degeneration of anterior horn cells [78]. 
Another interesting finding raised in this study is that the loss of GABAergic and 
 
 
glutamatergic synapses on MNs could result from the induction of neuronal nitric oxide 
synthase (nNOS), which is upregulated in SMNΔ7 MNs [67]. It is known that nitric oxide 
(NO) can induce synaptic degeneration following a physical injury to motor nerves; and is 
also found in ALS [79]. Moreover NO produced via up-regulation of nNOS could lead to 
activation of the RhoA/Rho kinase (ROCK) pathway [80]. This pathway is abnormally 
activated in the SMA mice, and ROCK inhibitor treatment improves maturation of the NMJ, 
and increases survival in treated mice [81]. 
 
4. Other cell types outside the central nervous system involved in SMA 
4.1. Peripheral nervous system involvement: Schwann cells 
Schwann cells are the main glial cells of the peripheral nervous system (PNS). There are two 
types of Schwann cells, myelinating and non-myelinating, that are both essential to axon 
stability and neuronal survival, notably through the production of proteins involved in the 
formation and maintenance of the extracellular matrix (ECM) [82,83]. In addition to this, 
myelinating Schwann cells also form the protective myelin sheath wrapping around axons of 
motor and sensory neurons, which allows a substantial increase in nerve conduction 
velocity. 
 
Myelinating Schwann cell dysfunction is known to play a crucial role in hereditary 
peripheral neuropathies that are usually associated with axonal atrophy and degeneration of 
lower motor and sensory neurons [84]. More recently, low levels of SMN were reported to 
cause changes in Schwann cells that lead to abnormal axon myelination and interrupted the 
deposition of extracellular matrix proteins in peripheral nerves (Figure 2) [85]. In this study, 
Hunter et al. (Table 1) demonstrated that Schwann cells, isolated from SMA mice, had 
reduced levels of SMN as expected, but did not respond normally to differentiation signals 
in culture. Concurrently, they observed morphological imperfections in myelination in SMA 
mice that were associated with alterations in the expression of myelin-associated proteins, 
such as peripheral myelin protein 22 (PMP22), myelin protein zero (MPZ), and myelin basic 
protein (MBP) [86]. They further demonstrated that primary Schwann cells derived from 
SMA transgenic mice cannot successfully myelinate healthy neurons in co-culture, and that 
they exert a detrimental influence on neuritic stability. One possible explanation for these 
changes could be that low levels of SMN impair the regulation of expression of myelin 
proteins, which normally occurs during postnatal development [85]. By genetically- 
correcting SMN levels in Schwann cells, Hunter et al. showed that these defects were SMN- 
dependent and reversible. Alternatively, these myelination defects could also be explained 
by the reduced capacity of SMA-derived Schwann cells to produce key proteins composing 
the ECM of peripheral nerves. This is supported by other studies showing that the 
expression levels of several ECM proteins, including laminin alpha 2 (LAMA2), are 
severely altered in the context of SMN deficiency [87,88]. Consistent with this, it was 
shown that impairment of extracellular laminin-mediated control of beta-actin translation is 
contributing to SMA motor neuron axonal defects [89]. 
 
To understand how SMN deficiency can disrupt Schwann cell physiological functions, 
Sarvestany and collaborators (2014) (Table 1) performed label-free proteomics analyses of 
Schwann cells obtained from SMA mouse peripheral nerve [90]. Through this approach, 
 
they found that several pathways were altered in SMA Schwann cells including growth, 
proliferation, cell death, survival and molecular transport. Of particular interest, functional 
cluster analysis revealed that ubiquitination pathways are profoundly disrupted in SMN- 
deficient Schwann cells. For example, reduced levels of ubiquitin-like modifier activating 
enzyme 1 (uba1) were observed [90]. In fact, suppression of Uba1 through pharmacological 
treatment in WT Schwann cells is sufficient to recapitulate the defective myelination 
phenotype presented by SMA Schwann cells [90]. Microarrary analyses of Schwann cell 
myelination-related genes revealed disrupted gene expression in tissue from SMA mice in 
comparison to WT [87,88]. 
 
Altogether, these data highlight the important role of the SMN protein in regulating the 
ubiquitination pathway and maintaining the homeostasis of Schwann cells. 
 
4.2. Neuromuscular junction and muscle cell involvement 
Longitudinal studies in a severe mouse model of SMA have revealed that early symptomatic 
stages of the disease are characterized by morphological and functional anomalies at the 
synapse; affecting both NMJs [76,65,23,91,24,92] and synaptic inputs to motor neurons in 
the spinal cord [24,25] (Table 1). To understand the underlying mechanisms of this early 
synaptic pathology in SMA, Martinez and colleagues have recently generated three lines of 
SMA mice that express increased levels of SMN in motor neurons and/or muscle [27]. In 
this study, they showed that the increase of SMN expression in motor neurons improved 
synaptic function both at the NMJ and motor neuron somas, whereas selective over- 
expression of SMN in muscle restores muscle mass without affecting synaptic integrity [27]. 
They concluded that SMN could have a role in the growth of muscle that is independent of 
its effect on motor neuron synaptic function; suggesting that SMN has multiple roles in the 
motor neuron unit (fig.2). 
 
Some studies have reported that high levels of SMN expression in muscle can affect the 
SMA phenotype in Drosophila melanogaster [93,5]. To investigate whether this is also the 
case in mammals, Gavrilina and colleagues (2008) (Table 1) have used transgenic SMA 
mouse models in which SMN expression is restored in skeletal muscle fibers under the 
human skeletal actin (HSA) promoter [94-96] and in neurons under the prion promoter (PrP) 
[97], which is also known to lead to high expression in astrocytes [97,7]. In this study, both 
lines were null for the murine smn gene, and homozygous for the human SMN2 gene. They 
found that full-length SMN expressed under the PrP promoter had a strong beneficial impact 
on survival and phenotype in the severe SMA mouse [7]. In contrast, restoration of SMN 
expression in muscle alone was unable to correct the phenotype of the disease. This 
confirms that re-establishment of SMN expression in neurons, and possibly astrocytes, is 
required for maximal disease-modifying effect in SMA [7]. Many studies have reported a 
direct or indirect interaction of SMN with molecular modulators of actin dynamics such as 
plastin 3, profilin, small Rho GTPases Cdc42 and RhoA, as well as ROCK, a direct 
downstream effector of RhoA [98-101]. If activity of the RhoA/ROCK pathway is increased 
in SMN-depleted neuronal cells and tissue, inhibition of actin-mediated neuronal outgrowth 
and differentiation is observed. Conversely, when SMA mice are treated with ROCK 
inhibitors, they show an improvement of skeletal muscle mass and NMJ morphological 
 
 
maturation and an accompanying increase in life span [103,81] (Table 1), with no change in 
the number of surviving motor neurons or in the expression of SMN protein [102]. 
 
SMN has also been implicated in myoblast fusion, proliferation and in the correct formation 
of myotubes [104-108] (Figure 2 and Table 1). Among its many functions, the RhoA/ROCK 
pathway is also involved at multiple points as, interestingly, it also regulates muscle 
contraction [109] and skeletal myogenesis [110]. It is possible that modulation of myogenic 
regulatory factors as well as actin-dependent myogenesis via regulation of ROCK signaling 
is sufficient to improve survival in mouse models of SMA. This raises the possibility that, to 
ameliorate disease progression, a modulation of myogenic regulatory factors and an actin- 
dependent regulation of myogenesis might be considered as a therapeutic target [102]. 
 
Altogether, these data demonstrate that the expression of high levels of SMN contribute to 
myofiber growth and development, but the full restoration of muscle fibers in severe form of 
SMA may require the targeting of other muscle cells, such as the satellite cells, which are 
crucial in the maintenance and regeneration of the muscle mass. This possibility is supported 
by the significant effects of ROCK inhibitors in SMA mice, which bypass the replacement 
of SMN full-length protein by targeting downstream pathogenic events. 
 
Other targets, independent of efforts to enhance SMN protein levels in muscle tissue, have 
been explored as possible disease-modifying approaches. Lorson and collaborators [111] 
investigated the role of follistatin, a cystine-rich glycoprotein that binds to and inhibits 
several TGF-β family members [23,24], including myostatin [5,9,25], in SMA progression. 
They demonstrated that recombinant adeno-associated virus (AAV) expression of follistatin 
enhances muscle mass in WT and SMA mice. This finding suggests that the administration 
of follistatin and the subsequent inhibition of the myostatin pathway are beneficial in SMA 
models as they preserve the expression of muscle-derived neurotrophic factors in SMA 
mice. 
 
Another substance beneficial for motor neuron survival is insulin-like growth factor I 
(IGF-1). Tsai and colleagues evaluated the efficacy of intravenous administration of a 
recombinant AAV1 vector encoding human insulin-like growth factor- 1 (IGF-1) in a severe 
mouse model of SMA. Affected mice treated with AAV1-IGF-1 on postnatal day 1 
exhibited reduced motor neuron degeneration, cardiac and muscle atrophy as well as a 
greater extent of innervation at the neuromuscular junctions compared to untreated 
transgenic mice. Moreover they demonstrated that treated animals had prolonged lifespan, 
increased body weight and improved motor coordination. Importantly, IGF-1 overexpression 
led to an increase in SMN protein levels in multiple tissues including spinal cord and muscle 
[112]; although the relevant site of action of IGF-1 for boosting SMN levels was not 
determined. 
 
Recently, our group [113] examined quadriceps muscle biopsies from 24 patients with 
genetically documented SMA, and paraspinal muscle biopsies from 3 patients with SMA-II. 
We found that cytochrome-c oxidase (COX) deficiency was more evident in muscle from 
patients with SMA-I and SMA-II compared to healthy controls, and that muscle mtDNA 
content and citrate synthase activity were also reduced in all 3 SMA types. Our results 
 
 
strongly support the conclusion that an altered regulation of myogenesis and downregulated 
mitochondrial biogenesis contribute to pathologic changes in the muscle of patients with 
SMA [113]. 
 
SMA patients also suffer from gastroesophageal reflux, constipation and delayed gastric 
emptying. Gombash and colleagues [114] employed two mouse models of SMA to 
determine whether functional gastrointestinal complications are a direct consequence of 
SMN deficiency or a secondary event. With this study they demonstrated that SMN 
deficiency in enteric nervous system (ENS) neurons caused constipation, delayed gastric 
emptying, slow intestinal transit and reduced colonic motility (similar to what is reported in 
SMA patients), in the absence of gross anatomical or histopathological abnormalities. In 
particular SMN deficiency led to disrupted ENS signaling to the smooth muscle of the colon 
but did not cause enteric neuron loss. Together these data implicate that the susceptibility of 
the ENS cells to SMN deficiency may underlie gastrointestinal symptoms often reported in 
SMA. 
 
4.3. Immune system dysfunction in SMA 
The extent of involvement of the immune system in SMA has not been studied in depth to 
this point. An original study from Dachs and colleagues (2011) (Table 1) investigated the 
stimulation of apoptosis and macrophage recruitment in SMA muscles. Surprisingly, 
macrophage infiltration in SMA muscle was approximately 25-50% lower in comparison to 
healthy controls. This observation was tissue-specific, as no differences were observed in 
the liver and spleen between WT and SMA mice [115]. The authors concluded that the 
muscle-specific reduction in macrophage infiltration results from a primary defect in the 
immune system of severe SMA mice, due to a specific atrophy of immune organs, such as 
spleen and thymus. Similar alterations, such as spleen atrophy and systemic immune 
aberrations were previously reported in murine models of ALS [116]. Considering the 
pathologic alteration identified in the immune system organs of SMA animals, this field of 
study will require further attention in SMA patients. 
 
4.4. Cardiac involvement 
The presence of heart alterations have been reported in the most severe forms of SMA; 
caused either by congenital anomalies manifesting during cardiogenesis [117-121], or 
secondary to autonomic nervous system defects [122-127]. Many authors suggest that in 
juvenile cases of SMA, in particular for SMA types I and II, the presence of cardiac 
involvement is likely secondary to chronic respiratory insufficiency, which is a common 
feature of the disease. Investigators hypothesized that ventricular arrhythmia, bundle-branch 
and atrioventricular blocks are provoked by pulmonary and respiratory defects, highlighting 
the importance of respiratory assistance in preventing the onset of cardiological alterations 
[128,118,126,119,127,121] (Table 1). While previous clinical reports of SMA I patients did 
not explicitly determine if the cardiac defects were secondary to respiratory distress; 
recently, however, congenital heart anomalies are being described more frequently upon 
autopsy and include: dilated right ventricle, atrial and ventricular septal defects. The most 
common congenital heart defect is an anomalous development of the heart, referred to as 
hypoplastic left heart syndrome [123,129,120]. Analysis performed by Rudnik-Schoneborn 
 
 
and collaborators support a crucial role for SMN protein in cardiac development. In fact, 
they found that among patients with a single copy of SMN2, the incidence of congenital 
septal defects is approaching 75%; whereas among people without SMA, its frequency is 
closer to 1 in 50 million [120]. 
 
Preclinical studies in animal models of SMA have confirmed the presence of cardiac 
dysfunction [130,131,15,132]. Shababi and collaborators (2010) (Table 1) compared the 
very severe model of SMA (Smn−/−, SMN2+/+) and the well-established severe model for 
SMA, SMAΔ7 model (Smn−/−, SMN2+/+; SMNΔ7+/+), to examine the role of SMN 
protein in cardiogenesis and the contribution of heart anomalies to the SMA pathological 
phenotype. In the very severe model, as early as the embryonic stage, there was evidence of 
cardiac remodeling, well in advance of motor neuron loss. In the SMAΔ7 mouse model, 
similar structural heart defects have been described in the early post-natal period. The 
authors suggested that oxidative stress could lead to cardiac fibrosis, which starts at the time 
of symptom onset and increases significantly in the following days (Figure 2) [132]. 
 
In addition to structural defects, there is increasing evidence that arrhythmia and 
cardiomyopathy are widespread in SMA patients. In light of this, Heier and collaborators 
(2010) (Table 1) investigated whether such phenotypes are also present in SMA mouse 
models. Transgenic mice developed a severe bradyarrhythmia characterized by heart block 
and reduced ventricular depolarization as early as 2 days of age, before the onset of 
neuromuscular symptoms (Figure 2). However, at later stages of the disease, dilated 
cardiomyopathy and as well as sympathetic innervation defects are involved in heart failure. 
Moreover, mice treated with trichostatin A, a histone deacetylase inhibitor, showed 
improved heart rate and cardiac size. An improvement in neuromuscular function was also 
noted; however, affected mice died as a result of persistent bradyarrhythmia. This work 
further strengthens the notion that the involvement of cardiac arrhythmia is an early and 
progressive feature of SMA [15]. 
 
Previously, Foust and collaborators (2010) demonstrated that early post-natal delivery of 
SMN1 in SMNΔ7 mice using self-complementary AAV type 9 (scAAV9) improves both 
life span and neuromuscular function [133]. Based on these findings, Bevan and colleagues 
(2010) (Table 1) studied the effects of scAAV9 treatment on heart defects in the SMNΔ7 
mouse model. They reported that treatment with scAAV9-SMN, also at the early post-natal 
stage, prevented bradycardia and the early development of dilated cardiomyopathy. They 
hypothesized that the success of this treatment was not only due to the targeting of spinal 
motor neurons, for which this subtype of AAV has a high tropism, but also to the 
transduction of autonomic nervous system neurons. However, as treated animals still 
exhibited contractility impairment, additional mechanisms, potentially initiated prior to the 
administration of the virus, are also involved in SMA-related heart defects. In fact, because 
the delivery of SMN1 was performed post-natally, it is difficult to conclude whether the 
remaining heart defects are due to embryonic autonomic nervous system dysfunction, or 
other cardiogenesis deficits [130]. Addressing this question, in 2012, Biondi and 
collaborators (Table 1) showed that cardiac alterations in type 2 SMA transgenic mice are 
largely caused by intrinsic heart defects and not by autonomic impairment [131]. They 
examined the effects of physical exercise on cardiorespiratory function in this SMA mouse 
 
model and observed many benefits, including a reduction in the delay of cardiac muscle 
maturation, a lessening of fibrosis, enhancement of cardiac electrical conduction velocity, 
and a decrease in arrhythmias and bradycardia; resulting in a partial restoration of cardiac 
function. In addition, their data show that the sympathetic system contributes to the 
amelioration of arrhythmia and bradycardia in this model [131,17]. 
 
In addition to direct effects on the structure and function of the heart itself, investigators 
have observed abnormalities in the vascular system of infants affected by SMA. Autonomic 
dysfunction and, particularly sympathetic dysfunction, has been hypothesized to be a 
primary source of the vascular perfusion abnormalities in SMA [134]. Vascular defects 
include coolness and poor perfusion of distal extremities; and occasional digital necrosis has 
been reported in SMA type I children [122]. Because vascular and innervation patterning are 
closely related, it is intuitively evident that there is an integral and codependent relationship 
between innervation and vascularization in motor neuron disease [135]. This occurs in 
particular in congenital or early infantile onset SMA when the growth and development of 
the vascular network is critical. 
 
Taken together, the findings from multiple preclinical in vivo studies and the emerging 
clinical findings in SMA patients, suggest a key role of SMN protein in cardiogenesis, 
providing a new area of investigation that could be essential for optimal clinical success in 
the treatment of SMA. 
 
4.5 Bone, pancreas and liver involvement 
The impact of SMN deficiency in bone, pancreas and liver has also been documented. It is 
known that for patients affected by SMA as well as in the various SMA animal models, 
there is a high incidence of fractures and hypercalcemia, indicative of a role of SMN protein 
in bone function. In particular, children affected by SMA often suffer from severe 
osteopenia and fractures after a minimal trauma. In the most severe cases, congenital bone 
fractures and thinner ribs have been reported [136]. Moreover, a decrease of bone mineral 
density with increasing age in SMA patients has also been described [137]. Recently, a 
study revealed a key role of SMN protein in skeletal development critically dependent upon 
an interaction between SMN protein and osteoclast stimulatory factor. It was hypothesized 
that osteoclast stimulatory factor and SMN play a joint role in the cellular signal 
transduction cascade regulating the release of factors that stimulate skeletal development 
[138]. 
 
Occasional cases of pathologic pancreatic defects associated with SMA have been reported; 
in particular, diabetes and alterations in glucose metabolism in SMA Type II and III patients 
[139], and acute pancreatitis in SMA Type I patients [140]. Also, the intermediate SMA 
mouse model is characterized by metabolic defects such as fasting hyperglycemia, glucose 
intolerance, hypersensitivity to insulin, and hyperglucagonemia [139]. In an in vivo model in 
which Smn (+/−) heterozygous mice were created, it was proposed that metabolic and 
pancreatic defects are independent of late stage SMA neuromuscular pathology [141]. Since 
hepatic and pancreatic dysfunction appeared after one month of age, and only in response to 
dietary challenge, it was reasoned that defects in these systems occur independently of 
SMA-associated neurodegeneration. Although suggestive of SMN-dependency in these 
 
 
tissues, further confirmation using conditional SMN knock-out mouse lines, or reversal of 
the phenotype by viral mediated restoration of SMN protein levels selectively within these 
tissues would be beneficial. Both mice and human specimens show an abnormal localization 
of glucagon-producing α-cells within the pancreatic islets and increased insulin-producing β 
cells, hyperinsulinemia and increased hepatic glucagon sensitivity. Because SMA patients 
often suffer from pancreatic defects, there is an added risk of employing valproic acid in 
clinical studies since it is well known to be associated with an increased risk of pancreatitis 
[142]. 
 
The most common metabolic defect reported consists of alterations in fatty acid metabolism, 
which occurs in severe patients and some younger SMA Type II patients [143,144]. 
Abnormal fatty acid metabolism is characterized by mild to moderate dicarboxylic aciduria 
and increased levels of esterified carnitine. However, the level of ketone bodies is normal, 
suggesting a specific defect in fatty acid metabolism of muscles rather than in the liver. In 
order to investigate whether a fatty acid metabolism defect is a consequence of muscle 
denervation and atrophy, fatty acid levels in the plasma of severe SMA infants were 
measured and compared with control patients. The investigators found an increased ratio of 
dodecanoic acid to tetradecanoic acid in all SMA patients. These data suggest that the fatty 
acid metabolism dysfunction in SMA is not the consequence of SMA-related immobility, 
systemic illness, muscle denervation, or muscle atrophy. Rather these abnormalities may be 
directly related to the loss of SMN1 or neighboring genes [144]. The importance of SMN 
protein in the development and function of the liver was demonstrated by Vitte and 
colleagues in 2004 using the Δ7 SMA in vivo model. In this study, a mutation in exon 7 of 
murine Smn induced liver failure and late embryonic lethality [145]. Subcutaneous injection 
of therapeutic oligonucleotide (ASO), which restores SMN protein levels, increased IGF-1 
levels in the liver and rescued the pathological phenotype [16], highlighting the involvement 
of liver in SMA. Defects in fatty acid metabolism can lead to a reduction in production, 
causing extreme muscle wasting in severe SMA patients. For this reason, the evaluation of 
lipid content in the liver will be informative with respect to the effects of SMN deficiency 
on metabolic abnormalities. 
 
5. Conclusions 
Currently, there are no effective treatments available for SMA. There are, however, multiple 
ongoing clinical trials showing promising efficacy in ameliorating certain disease 
phenotypes. Historically, for SMA as in other neurodegenerative diseases, neuronal 
degeneration was widely considered to be strictly cell autonomous and the sole contributor 
to the clinical expression of the disease. However, the past few years have seen the 
accumulation of an overwhelming body of evidence that other cell types in the CNS, such as 
astrocytes, microglia and sensory neurons; and even outside the CNS, such as Schwann 
cells, muscle cells or heart, can be key components in the disease initiation and/or 
progression, as well as in the emergence of clinical symptoms. Here, we have reviewed and 
discussed the increasingly recognized involvement of these different systems in SMA which 
can have great consequences for the development of optimal therapeutic strategies for this 
aggressive disease. 
 
 
 
Until recently, astrocytes and microglia were thought to be solely involved in the secondary 
response to a primary neuronal injury, via a process known as “reactive gliosis”. While the 
pathologic roles of glial cells in SMA have not been characterized as extensively as in other 
motor neuron diseases such as ALS, numerous alterations in SMA astrocytes and microglia 
could potentially initiate neurodegeneration as well as propagate injury. For example, 
restoration of SMN expression both in motor neurons and in astrocytes is necessary to 
greatly extend animal survival in a mouse model of SMA. In keeping with this, astrocytes 
and microglia should be thought as prime additional targets for the development of 
therapeutic interventions. Similarly, the roles of sensory neurons and Schwann cells have 
also recently gained prominence in the pathogenesis of SMA. In fact, several clinical 
observations made in type I SMA patients have indicated that these cells are also affected. In 
addition, other tissues outside the CNS contribute to the overall phenotype of SMA 
pathology. For example, several preclinical studies and clinical findings in SMA patients 
suggest that SMN protein plays an important role in cardiogenesis; these findings provide a 
new field of investigation that could be helpful to improve clinical success in the treatment 
of SMA. 
 
Thus, while it is likely that motor neurons have an increased vulnerability to SMN 
deficiency, the involvement of different tissue in SMA pathology, inside and outside the 
CNS, warrants further investigation. Currently, the accumulating evidence concerning the 
involvement of cell types other than motor neurons is creating a paradigm shift in SMA and 
many other neurodegenerative diseases; what should we target, when, how and for how 
long? As discussed in this review, a first important point regarding the future development 
of genetic therapy is to consider that restoration of SMN expression in both central 
compartments (neurons/astrocytes) and peripheral compartments (muscle/Schwann cells) 
will be essential for an ideal disease-modifying treatment for SMA. Thus, while it is now 
largely recognized that each cell type may require different levels of SMN to exert its proper 
biological role, the regulation of SMN levels within different tissues and systems during 
development in animal models and humans remains to be investigated. The elucidation of 
levels of SMN that are required, regionally and temporally, is central to the development of 
successful therapies (genetic or otherwise), not only for the most severe SMA patients but 
also for the milder type 2, 3 and 4 SMA patients who appear to be much less responsive to 
SMN-restorative strategies than Type 1 patients. In keeping with this, unraveling the 
molecular pathways in SMA-relevant cell types that are defective after the SMN 
requirement window has passed may open new therapeutic strategies downstream of SMN, 
which could be more beneficial to milder SMA patients with later onset. These are among 
the critical questions that future translational research must address to finally make a cure 
for SMA a reality. 
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Figure 1. 
Role of astrocytes and microglia in healthy subjects and SMA patients 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 2. 
The effects of SMA on non-motor neuronal tissue 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Table 1 
Summary of the participation different non-motor neuron cell types, intrinsin and extrinsic to the CNS, in 
SMA pathogenesis. PD: post natal day, MNs: motor neurons 
 
Involvement of non-motor neuronal cells located inside the CNS 
Cell Type Citation Disease model Observation 
 
 
 
 
 
 
 
 
Astrocytes 
 
 
 
 
 
McGivern 
2013 
 
SMAΔ7 
mouse 
(Smn−/−, 
SMN2+/+; 
SMNΔ7+/+) 
early PD: no differences between wt and 
SMA mice 
PD9 in SMA mice: augmented cell bodies; ↑ 
GFAP; thin and retracted processes 
production of pro-inflammatory cytokines 
through ERK1/2 activation 
SMA iPSC- 
derived 
astrocytes 
mis-regulation of basal calcium 
decreased response to adenosine 
triphosphate stimulation 
 
Tarabal 
2014 
 
SMAΔ7 
mouse 
GFAP-positive profiles from PD4 
↑ components of Notch signaling pathway, 
in particular Jagged 1 
 
 
 
Microglia 
 
 
Tarabal 
2014 
 
 
 
SMAΔ7 mouse 
↑ anti-Iba1 positive microglial cells from 
PD7 
CD68 positive microglial cells 
microglial clearance of cellular debris during 
synapse degeneration/elimination 
 
 
 
 
 
 
 
 
 
 
 
 
Interneurons and sensory 
neurons 
 
Jablonka 
2006 
SMA sensory 
neuron (E14 
embryos 
derived) 
smaller growth cones 
shorter neurites 
reduced βactin levels of mRNA and protein 
 
 
 
Schwab 
2014 
Co-colture 
with SMA 
iPS-derived 
sensory 
neurons and 
wt iPS-derived 
MNs 
 
 
 
SMA sensory neurons doesn’t contribute to 
MNs loss in this human stem cell system 
 
 
 
 
 
 
Lotti 
2012 
SMA 
Drosophila 
 
aberrant splicing of Stasimon gene 
 
isolated 
sensory 
neurons from 
Smn −/−;SMN2 
mouse 
embryos 
smaller terminal in the skin and 
defects both in neurite growth and growth 
cone morphology 
abnormal sensory conduction velocity 
axonal degeneration 
SMAΔ7 
mouse 
alteration of monosynaptic connections 
between sensory neurons and motor neurons 
Other cell types outside the CNS 
 
 
 
 
Heart involvement 
Elkoen 1996 
Distefano 1994 
Roos 2009 
Kimura 1980 
Takahashi 2006 
Takana 1976 
 
 
 
SMA I patients 
atrial and ventricular septal defects 
dilated right ventricle 
anomalous development of the heart 
 
Shababi 
2010 
severe model of 
SMA (Smn−/−, 
SMN2+/+) and 
 
cardiac fibrosis due to oxidative stress 
 
 
 
Involvement of non-motor neuronal cells located inside the CNS 
Cell Type Citation Disease model Observation 
  the SMAΔ7 mouse  
 
 
Heier 
2010 
 
 
SMAΔ7 mouse 
bradyarrhythmia from PD2 (heart block and 
reduced ventricular depolarization 
efficiency) 
sympathetic innervation defects and dilated 
cardiomyopathy at late stages of disease 
 
Bevan 
2010 
 
SMAΔ7 mouse 
bradycardia 
dilated cardiomyopathy 
 
 
 
Biondi 
2012 
 
 
 
type 2 SMA- 
like mice 
cardiac muscle maturation delay 
fibrosis 
alteration of cardiac electrical conduction 
velocity 
bradycardia and arrhythmia 
 
 
 
 
 
 
 
Schwann cells 
involvement 
 
 
 
Hunter 
2014 
 
Schwann cells 
derived from 
SMA mice 
↓ levels of SMN protein 
failed to respond normally to differentiation 
signals 
 
SMA mice 
alterations in the expression of key myelin 
proteins (MPZ, PMP22, MBP) 
↓ level of LAMA2 
 
 
Sarvestany 
2014 
 
 
Schwann cells 
isolated from 
SMA mice 
SMN-dependent disruption changes in 
growth/proliferation, cell death/survival, and 
molecular transport pathways, 
changes in ubiquitination pathways proteins 
such as Uba1 
 
 
 
 
Neuromuscular junction 
and muscle cells 
involvement 
Kong 2009 
Dachs 2013 
Ling 2010 
Kariya 2008 
Lee 2011 
Murray 2008 
Mentis 2011 
 
 
 
SMAΔ7 mouse 
 
 
 
morphological and functional abnormalities 
of synapses 
Bowerman 
2010 
 
SMAΔ7 mouse SMN levels in muscle fibers has no effects on SMA phenotype or on the survival 
 
 
 
 
Neuromuscular junction 
and muscle cells 
involvement 
Gavrilina 
2008 
 
SMAΔ7 mouse defect in cytoskeleton organization 
Arlnold 2004 
Boyer 2014 
Cifuettes-Diaz 2001 
Nicole 2003 
Shafey 2005 
 
 
SMAΔ7 mouse 
 
 
defect in in myoblast fusion, proliferation 
and in the correct formation of myotubes 
Dachs 
2013 
 
SMAΔ7 mouse 
 
↓ macrophage density 
 
 
 
 
 
 
 
 
 
 
